Domestic and International Exchange Dynamics-YINFENG LIFE EXTENSION PROGRAM

EN丨CN

International Life Extension Research Alliance

Domestic and International Exchange Dynamics

Video Center

【The YinFeng Life Continuation Project Debuts at the 2026 Annual Meeting of the Chinese Medical Association's Medical Ethics Branch—Ethics Leading Biotech Toward Benevolent Innovation】

Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross

Yinfeng Life Science Research Institute, in Collaboration with University of Science and Technology of China, Develops CryoSIM Platform, Published in Top Analytical Chemistry Journal Revolutionizing Oocyte Membrane Permeability Analysis Technology

Public Welfare Partnership: A Special Letter from the Jinan Red Cross

Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference

【The YinFeng Life Continuation Project Debuts at the 2026 Annual Meeting of the Chinese Medical Association's Medical Ethics Branch—Ethics Leading Biotech Toward Benevolent Innovation】

2026/07/22

The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.

Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross

2026/04/24

Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.

Yinfeng Life Science Research Institute, in Collaboration with University of Science and Technology of China, Develops CryoSIM Platform, Published in Top Analytical Chemistry Journal Revolutionizing Oocyte Membrane Permeability Analysis Technology

2026/03/04

The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.

Public Welfare Partnership: A Special Letter from the Jinan Red Cross

2026/02/02

On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).

World’s First Achievement Highlights Brand Leadership

2026/01/19

In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.

Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference

2026/01/04

Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.

2026-02-25

→

[World First] Pig Liver "Saves" Patient, China Achieves Another Major Breakthrough in Xenotransplantation Technology

Recently, Xijing Hospital of the Air Force Medical University announced that a team led by Academician Dou Kefeng, in collaboration with the First Affiliated Hospital of Sun Yat-sen University, Tangdu Hospital of the Air Force Medical University, and Sichuan Zhongke Aoger Biotechnology Co., Ltd., successfully completed the world's first surgery using "gene-edited pig liver extracorporeal perfusion" to treat a patient with liver failure. According to a technological novelty search, this procedure has no precedent internationally, marking another milestone breakthrough in the field of clinical xenotransplantation in China.

2026-02-25

→

Professor He Xiaoming Elected President of the Society for Cryobiology

2026-02-02

→

Public Welfare Partnership: A Special Letter from the Jinan Red Cross

2026-01-26

→

Breaking the Spinal Cord Repair Bottleneck: Novel Bio-3D Printing Technology Enables Functional Neural Regeneration

Once considered an irreversible "forbidden zone," the spinal cord is now gradually overcoming this cognitive barrier with the advent of NEAT technology. Harnessing the power of science and technology, more patients who have lost mobility due to neural injuries may one day see the dawn of regaining their ability to stand and live independently.

2026-01-26

→

Brain-on-a-Chip Model Constructed from Cryopreserved Human Brain Microvasculature Facilitates Brain Disease Research and Drug Testing

This research advances the intersection of bioengineering and neuroscience. The constructed "human cerebral vascular chip" represents the first comprehensive simulation of the human cerebral vascular system from structure to function. It provides an unprecedented in vitro platform for exploring cerebral blood flow regulation, BBB mechanisms, and brain diseases closely related to vasculature, such as neuroinflammation, Alzheimer's disease, and stroke.

2026-01-19

→

Chinese Team Publishes Revolutionary New Cancer Strategy in Nature: Developing a Novel Cancer Vaccine

Published in Nature, this research marks a shift in tumor immunotherapy from “target blockade” to “cellular fate reprogramming.” With ongoing optimization and clinical exploration of the iVAC platform, it holds promise as a core tool for the next generation of immunotherapies, offering new hope to millions of cancer patients.